Table 2.
Grading system | Grade | Key features | Ref. | |||
---|---|---|---|---|---|---|
FIGO | 1 | Well differentiated | Grade based on % solid non-squamous growth, grade + 1 if nuclear atypia apparent | <5% solid growth | [10] | |
2 | Moderately differentiated | 6–50% solid growth | ||||
3 | Poorly differentiated | >50% solid growth | [13] | |||
3-tier universal grading | 1 | Grade based on sum of individual feature scores (see right) 1 = 3–5 points 2 = 6–7 points 3 = 8–9 points |
Architecture based score | Glandular = 1 point Papillary = 2 points Solid = 3 points |
||
2 | Nuclear pleomorphism score | Slight = 1 point Moderate = 2 points Marked = 3 points |
[12] | |||
3 | Mitotic activity score | 0–9 = 1 point 10–24 = 2 points ≥25 = 3 points |
||||
2-tier grading | Serous tumour | Low grade (type I) | Slow development | Low chromosomal instability | Gene mutation–KRAS, BRAF, ERBB2 | [14] |
High grade (type II) | Rapid development | High chromosomal instability | Gene mutation–P53 | |||
Endomet roid tumour | Low grade | Well differentiated, no necrosis | Solid glandular architecture | Gene mutation–Wnt, PI3K/Akt | [13] | |
High grade | Solid growth >50%, necrosis | Diffusely infiltrative or expansive growth, no glandular architecture | Gene mutation–TP53 | [16] |